Research Review
CJC-1295, Ipamorelin, and PT-141: Mechanisms and Combination Research Guide
Why GHRH analogues and ghrelin-receptor agonists are studied together, how PT-141 differs, and what a well-controlled combination study needs.
Melanocortin · Lyophilized Powder
PT-141 (Bremelanotide) Research Peptide - 10mg Vial
CAS: 189691-06-3 | Sequence: Cyclic heptapeptide | Purity: ≥99.2%
$49.99 / vial
In Stock - Ships Within 24 Hours
- Cold Storage −20 °C lyophilized
- Reconstituted 2–8 °C · 28 days
- HPLC ≥99.2% third-party verified
SKU PT-PT141-10 · HPLC + MS tested every batch · Insulated cold-pack shipping
What Is PT-141?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide (1025.18 g/mol) analogue of α-melanocyte-stimulating hormone (α-MSH). A lactam bridge between Asp and Lys constrains its structure, and it differs from its parent compound Melanotan II mainly at the C-terminus (free acid instead of amide).
Bremelanotide is a melanocortin receptor agonist with activity at MC4R and MC3R, receptors densely expressed in hypothalamic nuclei that regulate motivated behaviours and energy balance. It is used to investigate central nervous system melanocortin pathways, as distinct from peripheral vascular mechanisms.
Supplied as 10 mg of lyophilized reference material at ≥99.2% HPLC purity with a batch-specific third-party COA. This is research-grade material, not a drug product — see the regulatory note in the Preclinical Research tab.
Third-Party Certificate of Analysis
Each production lot is independently tested for identity, purity and content. Select a batch to view its analytical results — your vial label lists the batch number.
HPLC purity (UV 220 nm)
99.42%
Tested by: —
| Test | Method | Result | Status |
|---|
PT-141 Scientific Documentation
Technical reference data and a summary of published preclinical literature, provided for educational purposes.
| Name | PT-141 (Bremelanotide) |
|---|---|
| Synonyms | Bremelanotide, PT-141 |
| CAS Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Molecular Weight | 1025.18 g/mol |
| Sequence (3-letter) | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Sequence (1-letter) | Ac-Nle-cyclo[DH(D-F)RWK]-OH |
| Structure Class | Cyclic heptapeptide melanocortin analogue (lactam bridge Asp–Lys); free-acid C-terminal metabolite analogue of Melanotan II |
| Form | White lyophilized powder |
| Purity | ≥99.2% (RP-HPLC); identity confirmed by ESI-MS |
| Content per Vial | 10 mg net peptide |
| Solubility | Soluble in water, bacteriostatic water and 0.9% saline |
| Storage Conditions | Lyophilized: −20 °C, desiccated and protected from light. Reconstituted: 2–8 °C, use within 28 days. |
The findings below come from in-vitro and animal studies and, where noted, clinical trials of approved pharmaceutical products. Bremelanotide is the active ingredient in an FDA-approved prescription medicine (Vyleesi®). The research-grade reference material sold here is not a drug product, is not manufactured under pharmaceutical cGMP, and must not be used as a substitute for any approved medicine, and nothing on this page is medical advice or a therapeutic claim.
Melanocortin Receptor Agonism
Bremelanotide is a non-selective melanocortin receptor agonist with activity at MC3R and MC4R (and MC1R). Structurally it is closely related to Melanotan II, differing at the C-terminus (free acid rather than amide).
Central Mechanism of Action
Unlike vascular-acting compounds, bremelanotide is studied for actions within the central nervous system, particularly hypothalamic melanocortin circuits. Female rat studies reported selective increases in appetitive sexual behaviours.
Cardiovascular Observations
Clinical pharmacology studies observed transient increases in blood pressure and decreases in heart rate after administration, a key safety consideration in the approved product labelling.
Melanocortin System Background
Endogenous melanocortins are cleaved from pro-opiomelanocortin (POMC) and act on five receptor subtypes (MC1R–MC5R). MC4R signalling in the paraventricular nucleus and related circuits links the melanocortin system to appetite, energy expenditure and sexual behaviour, making melanocortin agonists useful pharmacological probes.
Clinical Context
The approved product was evaluated in the RECONNECT phase 3 trials. Those data relate to the pharmaceutical product, not research-grade material.
Representative literature: Pfaus JG et al., Proc Natl Acad Sci USA 2004; Kingsberg SA et al., Obstet Gynecol 2019.
Bacteriostatic Water Ratio Chart (10 mg Vial)
| Diluent Added | Concentration | Per 0.1 mL Aliquot |
|---|---|---|
| 1.0 mL | 10.0 mg/mL | 1 mg |
| 2.0 mL | 5.0 mg/mL | 500 µg |
| 2.5 mL | 4.0 mg/mL | 400 µg |
| 3.0 mL | 3.33 mg/mL | 333 µg |
| 5.0 mL | 2.0 mg/mL | 200 µg |
Reconstitution Procedure
Allow the vial to reach room temperature. Introduce sterile or bacteriostatic water slowly down the inner glass wall — do not inject directly onto the powder cake. Swirl gently until fully dissolved; do not shake or vortex, as this can promote aggregation.
Temperature Stability
| State | Condition | Typical Stability |
|---|---|---|
| Lyophilized | −20 °C, desiccated | 24+ months |
| Lyophilized | 2–8 °C | Up to 12 months |
| Lyophilized | Room temp (≤25 °C) | Several weeks (transit) |
| Reconstituted | 2–8 °C | Up to 28 days |
| Reconstituted | −20 °C aliquots | Avoid repeated freeze–thaw |
Further Reading
Frequently Purchased Together
Complementary research compounds and lab supplies.